🇺🇸 FDA
Patent

US 11932692

Methods of treating cancer pain by administering a PD-1 inhibitor

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 11932692 (Methods of treating cancer pain by administering a PD-1 inhibitor) held by REGENERON PHARMACEUTICALS, INC. expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Mar 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
45
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K39/39558, A61P